Printer Friendly

The Role of Medications in the Employment of People with Schizophrenia.

Over the past half-century, many different vocational rehabilitation strategies have been used to help mental health consumers (that is, people with schizophrenia and other severe psychiatric disorders who experience significant difficulty in role functioning) obtain employment. For the most part, these efforts have been disappointing. The base rate for competitive employment for mental health consumers is less than 15% (Anthony & Blanch, 1987); long-term employment rates are not much increased by most psychiatric rehabilitation approaches (Bond, Drake, Becker, & Mueser, in press). By contrast, recent findings suggest that over half of mental health consumers enrolled in supported employment programs obtain competitive employment (Bond, Drake, Mueser, & Becker, 1997). Even with these encouraging results, the reality is that mental health consumers, especially those with schizophrenia, have much less favorable outcomes than other disability groups (Marshak, Bostick, & Turton, 1990).

The central premise of this article is that successful vocational rehabilitation programs for people with schizophrenia require careful attention to the management of psychiatric symptoms. Indirect support for this premise is found in studies showing that employment programs are more successful if they work closely with mental health treatment teams, including psychiatrists and case managers (Drake et al., 1999; Drake, McHugo, Becket, Anthony, & Clark, 1996). One important piece of this equation concerns the role of psychotropic medications. Although practitioners intuitively know that medications are inextricably involved in the rehabilitation process, the research literature has been woefully inadequate for answering the basic questions in this area.

Given the lack of pertinent research, it is not surprising to find that reviews of treatment for schizophrenia rarely integrate findings for medication and psychosocial interventions (Ballus, 1997; Johnson, 1977; Torrey, 1986; Vaccaro, Young, & Glynn, 1993). Reviews present drug and psychosocial treatments as separate domains, typically with an edict that both are necessary for the best treatment outcomes, but without articulating the interaction between the two. An even more striking omission is the lack of reviews discussing the role of medications in vocational rehabilitation.

The development of new medications for schizophrenia has resulted in renewed interest in the role of medications in work, particularly because they may play a more positive role than previously-used medications. The evidence for effectiveness of both the traditional and newer medications for schizophrenia will be reviewed in this article, as these findings have implications for rehabilitation counselors, employment specialists, and others involved in the rehabilitation process. To place this review in context, it begins with a brief description of the symptoms of schizophrenia and how they relate to vocational outcomes. The medications used to treat the symptoms and the side effects of schizophrenia will then be discussed, followed by a comment on how each affects vocational outcomes. Lastly, suggestions for rehabilitation professionals will be given.

Symptoms

People with schizophrenia experience two broad types of psychiatric symptoms, labeled as positive and negative. Positive symptoms are behaviors that are notably odd and socially deviant, such as hallucinations (sensory experiences in the absence of any environmental stimuli) and delusions (false beliefs, often bizarre and firmly held, even in the face of disconfirming evidence). The negative symptoms consist of patterns of nonresponsivity: passivity, a lack of spontaneity, flat affect (a lack of emotional responsivity), the inability to initiate goal-directed activity, social withdrawal, a lack of motivation, and anhedonia (an inability to experience pleasure) (Crow, 1980). Recently, cognitive deficits have received increasing attention (Green, 1996). Cognitive deficits include problems with memory, attention span and concentration, and executive functioning (judgment and decisionmaking).

Intuitively, one would think that positive symptoms would represent a major barrier to employment. Certainly, the stigma attached to schizophrenia among the general public (Link, Cullen, Frank, & Wozniak, 1987) and among rehabilitation counselors as well (Goodyear, 1983) derives largely from the stereotype of people with schizophrenia as having bizarre ideas and behaving unpredictably and possibly violently. Mental health consumers report that they have often been turned down for jobs for which they were qualified on the basis of their psychiatric illness (Wahl, 1997). Somewhat surprisingly, however, the positive symptoms of schizophrenia have not been strongly or consistently associated with poor vocational outcomes (Anthony & Jansen, 1984). Anecdotally, it is known that many people with florid positive symptoms of schizophrenia are able to work, perhaps because they are able to shut out positive symptoms while on the job. The homespun advice - "Don't talk about your delusions on the job" (Dunham, 1982, p. 41) - may in fact have some utility.

On the other hand, research suggests that negative symptoms can be a formidable barrier to successful employment. People with schizophrenia often do poorly in traditional vocational rehabilitation approaches requiring participants to look for jobs on their own. Thus, job clubs, which are used successfully by many rehabilitation clients, are largely ineffective for people with schizophrenia, who often drop out early in the process (Corrigan, Reedy, Thadani, & Ganet, 1995; Jacobs, Wissusik, Collier, Stackman, & Burkeman, 1992). A plausible explanation for the failure of this format for people with schizophrenia is that negative symptoms interfere with completing assignments within a job club program, such as initiating contacts with employers, initiating conversations, and responding appropriately during interviews. Negative symptoms also appear to interfere with performance on the job (including speed and quality of work and interpersonal relationships) (Bell & Lysaker, 1995; Hoffmann & Kupper, 1997; Lysaker & Bell, 1995).

Negative symptoms may affect vocational functioning in other ways. Hayes and Halford (1996) compared unemployed men with schizophrenia to employed men with schizophrenia and unemployed men with no psychiatric diagnosis. They found that the unemployed men with schizophrenia were socially withdrawn and slept more than 1.5 hours more per day, on average, than did men in the other two groups. An interpretation of this study is that unemployment exacerbates negative symptoms, leading to a cycle in which it becomes increasingly harder to become motivated to seek work.

Some preliminary research suggests that cognitive deficits in schizophrenia interfere with vocational functioning (Collaborative Working Group on Clinical Trial Evaluations, 1998; Green, 1996; Jaeger & Douglas, 1992; Lysaker, Bell, & Beam-Goulet, 1995; Meltzer & McGurk, 1999). In theory, the key cognitive deficits seen in schizophrenia (i.e., attention, memory, and executive function) should negatively impact social and vocational functioning. For example, persons with working memory deficits may have trouble remembering phone numbers, what happened a few minutes ago, or what they read at the beginning of a paragraph by the time they get to the end of it.

Traditional Antipsychotics

Although many different medications are used in the treatment of schizophrenia, this discussion will be limited primarily to antipsychotics, which are a group of medications used to treat symptoms of schizophrenia. With the emergence of new medications for schizophrenia starting in the 1980s, antipsychotics are now divided into traditional and atypical antipsychotics.

Effectiveness of traditional antipsychotics. The first widely used antipsychotic, chlorpromazine (Thorazine), was introduced into psychiatric hospitals in the United States in the 1950s. This led to a revolution in the treatment of schizophrenia, with a dramatic reduction over the next three decades in the number of psychiatric inpatients (Marder, Wirshing, & Ames, 1997). Among the most widely used antipsychotics have been thioridazine (Mellaril), fluphenazine (Prolixin), and haloperidol (Haldol). Although all antipsychotics are available in oral form, fluphenazine and haloperidol can also be taken in a long-acting injection form referred to as depot. A large body of research shows that people with schizophrenia receiving antipsychotics show substantial improvement over those receiving a placebo (Davis, 1980). Traditional antipsychotics reduce positive symptoms (Hirsch & Barnes, 1995), but their long-term effect on negative symptoms is minimal (Kane & Mayerhoff, 1989).

Side effects of traditional antipsychotics. Traditional antipsychotics have a variety of troublesome side effects. Among the most serious are extrapyramidal side effects (EPS), which include dystonic reactions, akathisia, and parkinsonism. Dystonic reactions are acute muscular spasms that occur mainly in the head and neck. Akathisia, the most common side effect of antipsychotics, is an inner restlessness that is manifested as an inability to sit still. Parkinsonism involves rigidity of joints, tremors, and a slowing of movements (Marder & May, 1986). About 60% of consumers who receive appropriate dosages of traditional antipsychotics develop EPS (Dawkins, Lieberman, Lebowitz, & Hsiao, 1999).

To combat these effects, patients often are given anticholinergic medication such as benztropine (Cogentin) or diphenhydramine (Benadryl). Parkinsonism can be treated with benztropine and trihexyphenidyl (Artane); however, akathisia usually does not respond to these medications (Janicak, Davis, Preskorn, & Ayd, 1997; Nurnberg & Levine, 1986; Sajatovic & Schulz, 1997). Unfortunately, anticholinergic medications have their own side effects, such as impairment in cognitive functioning, sedation, blurred vision, and dry mouth (Spohn & Strauss, 1989).

The most serious side effect of antipsychotics is tardive dyskinesia, a movement disorder involving involuntary movements such as lip-smacking and facial grimaces. The rate of tardive dyskinesia among patients treated with traditional antipsychotics for more than one year is at least 10% (Kane, Woerner, & Borenstein, 1986), and the cumulative risk is estimated to increase 5% each year the medication is taken (Dawkins et al., 1999). The main strategies to avoid this condition are to discontinue medications, reduce dosage levels, or change to one of the atypical antipsychotics (Bernstein, 1995).

Side effects present significant barriers to employment in two ways. First, they make it harder to perform tasks in the workplace. Akathisia, blurred vision, and sedation are obvious examples. Second, side effects make medication noncompliance more likely, setting off a cycle of relapse. Forty percent or more of people with schizophrenia do not take medications as prescribed (Cramer & Rosenheck, 1998; Streicker, Amdur, & Dincin, 1986), and those who do not take their medication as prescribed are more likely to relapse (Marder et al., 1997). The other significant point to be made about antipsychotics is that, even under the best of circumstances - excellent psychiatric management, cooperative consumers, and supportive family environment - they do not work for everyone. Approximately 30% do not respond to traditional antipsychotics (Dixon, Lehman, & Levine, 1995). Problems with relapse and rehospitalizations have obvious implications for the capacity to hold a job.

Historically, one indicator of "vocational readiness" has been medication compliance (Marrone, Horgan, Scripture, & Grossman, 1984). Medication compliance is influenced by many factors, including the desire for consumers to feel normal, and taking medications may serve as a reminder that they are not. Experiencing side effects is another major reason consumers give for noncompliance (Streicker et al., 1986). Interviews with consumers about their ways of coping with employment suggest that consumers are often ambivalent about medication. Although they acknowledge the role of medications in controlling symptoms and enabling them to function appropriately in the workplace, consumers also view the side effects that accompany medications as interfering with their ability to work (Kirsh, 1996). Thus, consumers admit that they often adjust the amount and frequency of medication they take, depending on the circumstances of the job and their judgment about the level of compliance needed to control symptoms (Alverson, Becker, & Drake, 1995). The other side of the coin is that employment may also be a positive motivator for consumers to take their medications if they believe that doing so is critical to holding their job.

Traditional antipsychotics and vocational outcomes. Since the introduction of antipsychotics, clinicians have looked toward medications as an avenue for improving vocational functioning. However, few studies have actually examined this issue. There were mixed results from some early, methodologically unsophisticated studies addressing the worry that the side effects of medications - especially sedation - would negatively impact work capacity. Mintz, Mintz, Hwang, and Uijtdehaage (1997) reviewed the relationship between antipsychotic medications and vocational functioning in five randomized double-blind clinical drug trials, concluding that traditional antipsychotics do not negatively impact vocational functioning.

A landmark study by Hogarty and Goldberg (1973) examined the interaction between medications and psychosocial interventions. The study was designed to experimentally test the independent effects of antipsychotic drugs and of a psychosocial intervention they called "sociotherapy," as well as the interaction between the two. Thus, the design involved random assignment to four groups: placebo alone, placebo and sociotherapy, drug alone, and drug and sociotherapy. Sociotherapy involved a combination of psychosocial interventions, including supportive therapy, social casework, and rehabilitation counseling. As expected, the group receiving drugs did significantly better in avoiding relapse than those receiving the placebo. The most important finding, however, was that the group receiving both antipsychotic medications and sociotherapy had the best long-term outcomes, including better instrumental role functioning (that is, working in competitive jobs and in homemaker roles). Those receiving sociotherapy and the placebo actually fared worse than those receiving the placebo alone. Remarkably, this single study is one of the few large-scale studies examining the additive effects of medications and psychosocial interventions on role functioning for people with schizophrenia. Despite the lack of direct evidence, the consensus in the psychiatric field is that effective treatment for schizophrenia includes a combination of both psychiatric rehabilitation and antipsychotics (Lehman et al., 1998a).

A number of studies have experimentally examined the impact of traditional antipsychotic dosage level on client functioning. Hogarty et al. (1988) compared a flexible, low dosage regimen to standard dosage. Their results suggested that a low dosage regimen could control symptoms as well as the standard regimen, with much reduced side effects and improvement in instrumental and interpersonal role performance. Other studies have failed to replicate these findings, however. The general consensus is that, while consumers report feeling more comfortable on low dosages of medication, as compared to standard dosages, there is little evidence that consumers actually improve in vocational functioning while on lower dosages (Mintz et al., 1997).

Atypical Antipsychotics

The atypical antipsychotics were developed with the goal of increasing the efficacy in the treatment of both positive and negative symptoms, while decreasing side effects, particularly tardive dyskinesia and EPS (Tamminga, 19971). Clozapine (Clozaril), risperidone (Risperdal), olanzapine (Zyprexa), and quetiapine (Seroquel) are examples of these new antipsychotics, each with its own unique pharmacological impact on the brain. Although we discuss atypicals as a group, their effectiveness and side effects vary. Clozapine, introduced in the United States in 1989, is reserved mostly for "treatment resistant" patients, that is, those who do not respond to traditional antipsychotics (Meltzer, 1995). Because of the risk of agranulocytosis (dangerously low white blood count), clozapine must be monitored closely. Risperidone was introduced to the United States market in 1994, followed by olanzapine in 1996 and quetiapine in 1997. Increasingly, olanzapine and risperidone are being used as "first line" medications for schizophrenia, that is, they are prescribed when schizophrenia is first diagnosed (Chiles et al., 1999). One disadvantage of atypicals is that none is yet available in depot form (Dawkins et al., 1999).

Effectiveness of atypicals. Clozapine is dramatically more effective than traditional antipsychotics in controlling positive symptoms in treatment-resistant patients (Marder, 1996). Aside from clozapine, atypicals are at least as effective as traditional antipsychotics in reducing positive symptoms and may be somewhat more effective than traditional medications in treating negative symptoms, although the efficacy in treating negative symptoms has not been clearly demonstrated (Dawkins et al., 1999; Moiler, Muller, Borison, Schooler, & Chouinard, 1995; Tamminga, 1997; Tollefson & Sanger, 1997). A review of 17 randomized controlled trials comparing atypicals with traditional antipsychotics found a small, but significant, effect on negative symptoms favoring atypicals (Grilli Tissot & Elkis, 1999).

Research on the effects of atypicals on cognitive functioning in schizophrenia is just beginning to appear in the literature. These cognitive improvements from the use of atypicals may be the indirect result of a decrease in EPS and decrease in the use of antiparkinsonian medication (which has been linked to cognitive impairments) (Green & Nuechterlein, 1999; Spohn & Strauss, 1989; Stip & Lussier, 1996). A review by Meltzer and McGurk (1999) concluded that atypicals clearly help cognitive functioning, but that the specific cognitive effects for each atypical appear to be somewhat different. They concluded that (1) there is strong evidence that clozapine improves attention and verbal fluency, and moderate evidence that clozapine improves some types of executive functioning; (2) risperidone has a relatively consistent positive effect on working memory, executive functioning, and attention; (3) preliminary evidence suggests that olanzapine improves verbal learning and memory, verbal fluency, and executive functioning. Based on a meta-analysis of 15 studies, Keefe, Silva, Perkins, and Lieberman (1999) also concluded that consumers using atypicals had significantly better cognitive functioning than those on traditional antipsychotics. Overall, atypicals may have a more positive effect than traditional antipsychotics on cognitive functioning, not only because traditional antipsychotics may interfere with cognitive functioning, but also because atypicals may improve cognitive functioning.

Side effects of atypicals. Compared to traditional antipsychotics, atypicals have fewer EPS side effects (Lieberman, 1996), although weight gain has been reported with some atypicals (Casey, 1996). It has been speculated that the generally reduced side effect profiles for atypicals may lead to greater satisfaction with medications (Zygmunt, Emmanuel, Weiden, & Nathan, 1997) and therefore greater medication compliance. Consistent with this view, some of the original clinical trials suggested higher rates of continued use of atypicals compared to traditional medications (Song, 1997; Tollefson & Sanger, 1997). However, a naturalistic study of risperidone use among patients discharged from a psychiatric hospital found that only 29% remained on the drug after 2 years (Binder, NcNiel, & Sandberg, 1998), reminding us that medication noncompliance and discontinuation is a problem for the atypicals as well.

Atypical antipsychotics and vocational outcomes. If atypicals do prove to be more effective than traditional antipsychotics in the areas of negative symptoms, cognitive functioning, and side effects, then it is reasonable to expect an improvement in vocational functioning with their use. Consequently, it has been speculated that atypicals will allow more people with schizophrenia to benefit from rehabilitation programs than was true in the past (Weiden, Aquila, & Standard, 1996). To date, only a few studies have examined the direct impact of medication type on vocational functioning. Unfortunately, vocational functioning has usually been measured as part of a general quality of life measure. These studies generally have not reported detailed information on work outcomes (Franz, Lis, Pluddemann, & Gallhofer, 1997; Meltzer, Burnett, Bastani, & Ramirez, 1990; Meltzer, Cola, & Way, 1993; Rosenheck et al., 1998; Tran et al., 1997).

Lindstrom and Lundberg (1997) followed 122 consumers on clozapine for a mean of 5.2 years. None of them were working initially, but 40% were working in full- or part-time employment after a minimum of 2 years' treatment. Another uncontrolled follow-up study also found encouraging employment outcomes for consumers on clozapine (Littrell, 1995).

Noordsy and O'Keefe (in press) examined work outcomes for 67 consumers, 6 months after switching from a traditional antipsychotic to olanzapine. Pre-post ratings by case managers showed significant improvement in symptoms and in psychosocial functioning, including vocational functioning. The authors speculate that improvements in cognitive functioning may have led to "synergistic interactions contributing to functional outcomes." As a part of a multi-site randomized clinical trial, Hamilton, Genduso, and Revicki (1998, as described in Glazer, 1998) examined one-year outcomes for consumers receiving olanzapine or haloperidol. At baseline, the two groups had similar employment rates (11% and 9%, respectively). By one-year follow-up, 19% of the olanzapine group were competitively employed, compared to 8% of the haloperidol group, a significant difference, although the employment rate was small even for the olanzapine group. In a cross-sectional study of 82 consumers attending a psychiatric rehabilitation program, Bond et al. (1998) found no differences in employment outcomes between consumers receiving atypicals and those receiving traditional medications. However, the investigators found a significant increase in the annual number of weeks worked in paid employment from 12.7 weeks prior to the switch to an atypical, to 28.3 weeks after switching.

Two weaknesses in this group of studies are that none has used a rigorous research design, nor has any studied atypical in conjunction with a well-implemented supported employment program, that is, the vocational approach which has the strongest evidence for effectiveness. The hope is that if both state-of-the-art medications and best practices vocational services are offered, consumers will show substantial gains in employment.

Implications for Practitioners

This review has several implications for rehabilitation practitioners involved in the vocational rehabilitation of people with schizophrenia and other severe psychiatric disabilities. The first suggestion is, quite simply, for rehabilitation professionals to become educated about the nature of psychiatric disorders, through a thorough acquaintance with the Diagnostic and Statistical Manual, 4th Edition (American Psychiatric Association, 1994), as a precondition for understanding medications. An understanding of the positive and negative symptoms of schizophrenia is essential to avoid misattributing characteristics of the illness to "laziness" or "lack of motivation" (Braitman et al., 1995). Information on psychiatric diagnosis is widely available in many sources, ranging from technical manuals (American Psychiatric Association, 1994) to abnormal psychology textbooks and guides for the general public (Mueser & Gingerich, 1994; Torrey, 1995). It is equally important to realize that symptoms are an uncertain predictor of capacity to work (Anthony & Jansen, 1984) and should not be used to screen consumers out from receiving rehabilitation services.

Rehabilitation professionals also should acquire a rudimentary knowledge of psychotropic medications, especially in light of the recent revolution in the development not only of the atypical antipsychotics, but other medications as well. Rehabilitation professionals should have access to such resources as practical guides to psychopharmacology (e.g., Gorman, 1998; Gitlin, 1996; Kaplan & Sadock, 1996; Preston, O'Neal, Talaga, 1998) and videotapes made for this purpose (e.g., Center for Mental Health, 1996). In this rapidly changing field, it should be remembered that such sources quickly become outdated. Because of this, continuing education also is essential for rehabilitation professionals to stay current.

Another principle is to select and tailor jobs that take into consideration each consumer's specific symptoms, medication use, and side effects. Successful rehabilitation programs help consumers find jobs that truly are compatible with their preferences, strengths, weaknesses (Becker & Drake, 1994), and, we would add, their medications. For rehabilitation counselors to be successful in this regard, they must listen carefully to consumers. Medications are an element in the day-to-day reality for consumers: to treat medications as a "medical issue" and of no relevance to vocational rehabilitation is a misguided policy.

Job matching includes selecting work environments that are tolerant of consumers' behaviors and symptoms. For example, a consumer who becomes paranoid in groups may be more successful working alone in the evenings (Torrey et al., 1998). When consumers choose to disclose their disability to employers, rehabilitation professionals also may enlist employers in providing accommodations for symptoms and medications. Examples include: (1) allowing workers with dry mouth to drink water at their work space, (2) giving workers with motor side effects more time to perform tasks, (3) giving workers with memory or concentration problems concrete written instructions, and (4) giving workers who are restless more breaks or permission to walk around. In addition, workers on medication may need flexibility in their work schedule to keep psychiatrist appointments (Mancuso, 1990).

A further principle is that rehabilitation professionals should work closely with the consumer's treatment team (Becker & Drake, 1994). Lehman et al. (1998b) found that less than 50% of mental health consumers in mental health treatment were actually receiving psychotropic medications consistent with best practice recommendations, so that employment specialists first should make sure that consumers are receiving basic, proper psychiatric attention. The employment specialist often has critical information that may be of help to the psychiatrist in titrating medications; conversely, the psychiatrist has expertise on features of the medications that may affect work. Rehabilitation professionals should be allies with the treatment team, reinforcing messages about the importance of medications for getting and keeping jobs. Increased contact with others in the work place may help motivate consumers to take medications as prescribed (Draine & Solomon, 1994). Conversely, starting a new job may require adjustments in medication dosage or type, or scheduled times for taking medication. For example, if a medication has sedating effects, then it may be advisable to take it before bedtime and not before work (Torrey et al., 1998). Similarly, medication changes initiated by the treatment team should be closely coordinated with the vocational team. For example, if a consumer is beginning a new medication, it might be wise to postpone starting a new job until the effects of the medication change are clear (Torrey et al., 1998). The important principle here is active communication between rehabilitation and treatment staff, as has been carefully articulated in current supported employment models (Becket & Drake, 1994).

Conclusions

Research over the past four decades on the role of traditional antipsychotics in vocational rehabilitation has not yielded dramatic findings. One reason may be that these drugs mainly reduce positive symptoms, which do not appear to be that closely linked to vocational functioning. The development of new medications for schizophrenia has led to renewed attention to the interrelationship between medications and rehabilitation. The hope is that these new medications may have an impact on areas of functioning directly relevant to successful employment. However, research on the impact of atypicals on role functioning is still very primitive. Moreover, a healthy skepticism should be exercised in assessing the findings from studies funded by pharmaceutical companies. When a new treatment is discovered, it is often accompanied by unbridled enthusiasm, followed later by a more sober assessment. Nonetheless, early studies on atypicals are encouraging for their impact on rehabilitation.

The focus on the role of medications in the vocational process should not obscure the fact that medications alone are not sufficient to improve employment outcomes. Well-implemented vocational programs following validated program models appear to be a necessary ingredient to achieve this goal. The best outcomes are likely when both medications and employment services are considered together. To date, no research has examined the effects of the atypicals in combination with supported employment, which growing evidence suggests improves employment outcomes for people with severe mental illness (Bond et al., 1997).

Future research should examine the impact of side effects on vocational functioning, as well as how side effects serve as a barrier to successful employment. In addition, very little is known about how medications improve vocational functioning and in what areas the improvement actually takes place, such as social relationships on the job, social skills in general, job retention, motivation, and general health. Lastly, there is a lack of literature exploring how employment may facilitate appropriate use of medications. Answers to these questions would help to improve vocational outcomes for persons with schizophrenia.

Work on this paper was partly supported by National Institute of Mental Health Grant 00842 to the first author. We thank Lisa Evans, Hea-Won Kim, Sandy Resnick, and Angie Rollins for their helpful comments on earlier drafts.

References

Alverson, M., Becket, D. R., & Drake, R. E. (1995). An ethnographic study of coping strategies used by people with severe mental illness participating in supported employment. Psychosocial Rehabilitation Journal, 18(4), 115-128.

Anthony, W. A., & Blanch, A. (1987). Supported employment for persons who are psychiatrically disabled: An historical and conceptual perspective. Psychosocial Rehabilitation Journal. 11 (2), 5-23.

Anthony, W. A., & Jansen, M. A. (1984). Predicting the vocational capacity of the chronically mentally ill: Research and implications. American Psychologist, 39, 537-544.

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.

Ballus, C. (1997). Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia. Schizophrenia Research, 28, 247-255.

Becker, D. R., & Drake, R. E. (1994). Individual placement and support: A community mental health center approach to vocational rehabilitation. Community Mental Health Journal, 30, 193-206.

Bell, M. D., & Lysaker, P. H. (1995). Psychiatric symptoms and work performance among persons with severe mental illness. Psychiatric Services, 46, 508-10.

Bernstein, J. G. (1995). Handbook of drug therapy in psychiatry (3rd ed.). St. Louis: Mosby.

Binder, R. L., McNiei, D. E., & Sandberg, D. A. (1998). A naturalistic study of clinical use of risperidone. Psychiatric Services, 49, 524-526.

Bond, G. R., Drake, R. E., Becket, D. R., & Mueser, K. T. (in press). Effectiveness of psychiatric rehabilitation approaches for employment of people with severe mental illness. Journal of Disability Policy Studies.

Bond, G. R., Drake, R. E., Mueser, K. T., & Becker, D. R. (1997). An update on supported employment for people with severe mental illness. Psychiatric Services, 48, 335-346.

Bond, G. R., Meyer, P., Rollins, A., McCoy, M., Herbeck, D., & Rowan, D. (1998). The impact of atypical antipsychotics on vocational outcomes in a psychiatric rehabilitation agency. (Final Report to Eli Lilly). Indianapolis, IN: Indiana University-Purdue University Indianapolis.

Braitman, A., Counts, P., Davenport, R., Zurlinden, B., Rogers, M., Clauss, J., Kulkarni, A., Kymla, J., & Montgomery, L. (1995). Comparison of barriers to employment for unemployed and employed clients in a case management program: An exploratory study. Psychiatric Rehabilitation Journal. 19(1), 3-18.

Casey, D. E. (1996). Side effect profiles of new antipsychotic agents. Journal of Clinical Psychiatry, 57(Suppl 11), 46-52.

Center for Mental Health. (1996). Moving ahead with a vision: Psychopharmacology and work (videotape). Anderson, IN: Center for Mental Health.

Chiles, J. A., Miller, A. L., Crismon, M. L., Rush, A., J., Krasnoff, A. S., & Shon, S. S. (1999). The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatric Services, 50, 69-74.

Collaborative Working Group on Clinical Trial Evaluations. (1998). Evaluating the effects of antipsychotics on cognition in schizophrenia. Journal of Clinical Psychiatry, 59 (Supplement 12), 35-40.

Corrigan, P. W., Reedy, P., Thadani, D., & Ganet, M. (1995). Correlates of participation and completion in a job club for clients with psychiatric disability. Rehabilitation Counseling Bulletin, 39, 42-53.

Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196-201.

Crow, T. J. (1980). Molecular pathology of schizophrenia: More than one disease process? British Medical Journal, 280, 66-68.

Davis, J. M. (1980). Antipsychotic drugs. In H. I. Kaplan, A. M. Freedman, & B. J. Sadock (Eds.), Comprehensive textbook of psychiatry (Vol. 3, pp. 2257-2289). Baltimore: Williams & Wilkins.

Dawkins, K., Lieberman, J. A., Lebowitz, B. D., & Hsiao, J. K. (1999). Antipsychotics: Past and future. Proceedings of the National Institute of Mental Health division of services and intervention research workshop. Schizophrenia Bulletin, 25, 395-404.

Dixon, L. B., Lehman, A. F., & Levine, J. (1995). Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21, 567-577.

Draine, J., & Solomon, P. (1994). Explaining attitudes toward medication compliance among a seriously mentally ill population. Journal of Nervous and Mental Disease. 182, 50-54.

Drake, R. E., McHugo, G. J., Bebout, R. R., Becker, D. R., Harris, M., Bond, G. R., & Quimby, E. (1999). A randomized clinical trial of supported employment for inner-city patients with severe mental illness. Archives of General Psychiatry, 56, 627-633.

Drake, R. E., McHugo, G. J., Becker, D. R., Anthony, W. A., & Clark, R. E. (1996). The New Hampshire study of supported employment for people with severe mental illness: Vocational outcomes. Journal of Consulting and Clinical Psychology, 64, 391-399.

Dunham, C. (1982). Don't talk about your delusions on the job: An experience with competitive job placement in psychiatric rehabilitation. Psychosocial Rehabilitation Journal, 5(1), 41-46.

Franz, M., Lis, S., Pluddemann, K., & Gallhofer, B. (1997). Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 170, 422-425.

Gitlin, M. J. (1996). The psychotherapist's guide to psychopharmacology (2nd ed.). New York: Free Press.

Glazer, W. M. (1998). Formulary decisions and health economics. Journal of Clinical Psychiatry, 59(Suppl 19), 23-29.

Goodyear, R. K. (1983). Patterns of counselor attitudes toward disability groups. Rehabilitation Counseling Bulletin, 26, 181-184.

Gorman, J. M. (1998). The essential guide to psychiatric drugs. St. Martin's Press.

Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.

Green, M. F., & Nuechterlein, K. H. (1999). Conceptual frame works: Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin, 25, 309-319.

Grilli Tissot, M. C., & Elkis, H. (1999). Meta-analyses of randomized controlled trials which compared the effect of typical versus atypical neuroleptics on negative symptoms in schizophrenia [Abstract]. Schizophrenia Research, 36, 281.

Hamilton, S. H., Genduso, L. A., & Revicki, D. A. (1998, February). Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders. Paper presented at the Ninth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland.

Hayes, R. L., & Halford, W. K. (1996). Time use of unemployed and employed single male schizophrenic subjects. Schizophrenia Bulletin, 22, 659-669.

Hirsch, S. R., & Barnes, T. R. E. (1995). The clinical treatment of schizophrenia with antipsychotic medication. In S. R. Hirsch & D. R. Weinberger (Eds.), Schizophrenia (pp. 443-468). Cambridge, MS: Blackwell Science.

Hoffmann, H., & Kupper, Z. (1997). Relationships between social competence, psychopathology and work performance and their predictive value for vocational rehabilitation of schizophrenic outpatients. Schizophrenia Research, 23, 69-79.

Hogarty, G. E., & Goldberg, S. C. (1973). Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry, 28, 54-64.

Hogarty, G. E., McEvoy, J. P., Munetz, M., DiBarry, A. L., Bartone, P., Cather, R., Cooley, S. J., Ulrich, R. F., Carter, M., & Madonia, M. J. (1988). Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Archives of General Psychiatry, 45, 797-805.

Jacobs, H. E., Wissusik, D., Collier, R., Stackman, D., & Burkeman, D. (1992). Correlations between psychiatric disabilities and vocational outcome. Hospital and Community Psychiatry, 43, 365-369.

Jaeger, J., & Douglas, E. (1992). Neuropsychiatric rehabilitation for persistent mental illness. Psychiatric Quarterly, 63, 71-94.

Janicak, P. G., Davis, J. M., Preskorn, S. H., & Ayd, F. J. (1997). Principles and practice of psychopharmacotherapy (2nd ed.). Baltimore: Williams & Wilkins.

Johnson, D. A. (1977). Treatment of chronic schizophrenia. Drugs, 14, 291-299.

Kane, J. M., & Mayerhoff, D. (1989). Do negative symptoms respond to pharmacological treatment? British Journal of Psychiatry, 155 (Supplement 7), 115-118.

Kane, J. M., Woerner, M., & Borenstein, M. (1986). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin, 22, 254-258.

Kaplan, H. I., & Sadock, B. J. (1996). Pocket handbook of psychiatric drug treatment (2nd ed.). Lippincott: Williams & Wilkins.

Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and metaanalysis. Schizophrenia Bulletin, 25, 201-222.

Kirsh, B. (1996). Influences on the process of work integration: The consumer perspective. Canadian Journal of Community Mental Health, 15, 21-37.

Lehman, A. F., Steinwachs, D. M., Dixon, L. B., Goldman, H. H., Osher, F., Postrado, L., Scott, J. E., Thompson, J. W., Fahey, M., Fischer, P., Kasper, J. A., Lyles, A., Skinner, E. A., Buchanan, R., Carpenter, W. T., Jr., Levine, J., McGlynn, E. A., Rosenheck, R., & Zito, J. (1998a). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24, 1-10.

Lehman, A. F., Steinwachs, D. M., & PORT Co-Investigators. (1998b). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Survey. Schizophrenia Bulletin, 24, 11-20.

Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Journal of Clinical Psychiatry, 57 (Suppl 11), 68-71.

Lindstrom, L. H., & Lundberg, T. (1997). Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients. European Psychiatry, 12 (Supplement 5), 353s-355s.

Link, B. G., Cullen, F. T., Frank, J., & Wozniak, J. F. (1987). The social rejection of former mental patients: Understanding why labels matter. American Journal of Sociology, 92, 1461-1500.

Littrell, K. (1995). Maximizing schizophrenia treatment outcomes: A model for integration. Psychiatric Rehabilitation Journal, 19(1), 75-77.

Lysaker, P., & Bell, M. (1995). Negative symptoms and vocational impairment in schizophrenia: Repeated measurements of work performance over six months. Acta Psychiatrica Scandinavica, 91, 205-208.

Lysaker, P., Bell, M., & Beam-Goulet, J. (1995). Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatry Research, 56, 45-51.

Mancuso, L. L. (1990). Reasonable accommodation for workers with psychiatric disabilities. Psychosocial Rehabilitation Journal, 14(2), 3-19.

Marder, S. R. (1996). Management of treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry, 57 (Suppl 11), 26-30.

Marder, S. R., & May, P. R. (1986). Benefits and limitations of neuroleptics--and other forms of treatment--in schizophrenia. American Journal of Psychotherapy, 40, 357-369.

Marder, S. R., Wirshing, W. C., & Ames, D. (1997). Overview of antipsychotic medications. In D. C. Dunner (Ed.), Current psychiatric therapy II (pp. 211-216). Philadelphia: W. B. Saunders Company.

Marrone, J., Horgan, J., Scripture, D., & Grossman, M. (1984). Serving the severely psychiatrically disabled client within the VR system. Psychosocial Rehabilitation Journal, 8(2), 5-23.

Marshak, L. E., Bostick, D., & Turton, L. J. (1990). Closure outcomes for clients with psychiatric disabilities served by the vocational rehabilitation system. Rehabilitation Counseling Bulletin, 33, 247-250.

Meltzer, H. Y. (1995). Atypical antipsychotic drug therapy for treatment resistant schizophrenia. In S. R. Hirsch & D. R. Weinberger (Eds.), Schizophrenia (pp. 485-502). Cambridge, MA: Blackwell Science.

Meltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.

Meltzer, H. Y., Cola, P., & Way, L. (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.

Meltzer, H. Y., & McGurk, S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25, 233-255.

Mintz, J., Mintz, L. I., Hwang, S. S., & Uijtdehaage, S. (1997). Work outcomes in depression and schizophrenia (Final Report MH51112-02). Los Angeles: UCLA Department of Psychiatry.

Moller, H. J., Muller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995). A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American Risperidone Study. European Archives of Psychiatry & Clinical Neuroscience, 245, 45-49.

Mueser, K. T., & Gingerich, S. (1994). Coping with schizophrenia: A guide for families. Oakland, CA: New Harbinger Publications.

Noordsy, D., & O'Keefe, C. (in press). Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC setting. Journal of Clinical Psychiatry. Nurnberg, H. G., & Levine, P. E. (1986). Schizophrenia and antipsychotic drugs. Comprehensive Therapy, 12, 42-52.

Preston, J. D., O'Neal, J. H., & Talaga, M. C. (1998). Consumer's guide to psychiatric drugs. Oakland, CA: New Harbinger Publications.

Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., Thomas, J., Henderson, W., & Charney, D. (1998). Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry, 55, 618-625.

Sajatovic, M., & Schulz, S. C. (1997). Schizophrenia. In D. L. Dunner (Ed.), Current psychiatric therapy II (2nd ed., pp. 181-191). Philadelphia: W.B. Saunders Company.

Song, F. (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 11, 65-71.

Spohn, H. E., & Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 367-380.

Stip, E., & Lussier, I. (1996). The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry, 41(8 Suppl 2), S35-S40.

Streicker, S. K., Amdur, M., & Dincin, J. (1986). Educating patients about psychiatric medications: Failure to enhance compliance. Psychosocial Rehabilitation Journal, 9(4), 15-28.

Tamminga, C. A. (1997). The promise of new drugs for schizophrenia treatment. Canadian Journal of Psychiatry, 42, 265-273.

Tollefson, G. D., & Sanger, T. M. (1997). Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466-74.

Torrey, E. F. (1986). Management of chronic schizophrenic outpatients. Psychiatric Clinics of North America, 9, 143-151.

Torrey, E. F. (1995). Surviving schizophrenia: A manual for families, consumers, and providers (3rd ed.). New York: HarperCollins.

Torrey, W. C., Bebout, R., Kline, J., Becker, D. R., Alverson, M., & Drake, R. E. (1998). Practice guidelines for clinicians working in programs providing integrated vocational and clinical services for persons with severe mental disorders. Psychiatric Rehabiliation Journal, 21(4), 388-393.

Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C., Jr., & Tollefson, G. D. (1997). Doubleblind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology, 17, 407-418.

Vaccaro, J. V., Young, A. S., & Glynn, S. (1993). Community-based care of individuals with schizophrenia. Psychiatric Clinics of North America, 16, 387-399.

Wahl, O. (1997). Consumer experience with stigma: Results of a national survey. Alexandria, VA: NAMI.

Weiden, P. J., Aquila, R., & Standard, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57(Suppl 11), 53-60.

Zygmunt, A., Emmanuel, M., Weiden, P., & Nathan, K. (1997, October). Effectiveness of olanzapine for vocational rehabilitation outcome in schizophrenia. Paper presented at the American Psychiatric Association Psychiatric Services Meeting, Washington, DC.

Piper S. Meyer

Indiana University-Purdue University Indianapolis

Gary R. Bond, Department of Psychology - LD 124, IUPUI, 402 North Blackford Street, Indianapolis, IN 46202-3275. Email: gbond@iupui.edu.
COPYRIGHT 1999 National Rehabilitation Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Meyer, Piper S.
Publication:The Journal of Rehabilitation
Geographic Code:1USA
Date:Oct 1, 1999
Words:6701
Previous Article:Stigmatic and Mythical Thinking: Barriers to Vocational Rehabilitation Services for Persons with Severe Mental Illness.
Next Article:An Individualized Job Engagement Approach for Persons with Severe Mental Illness.
Topics:


Related Articles
Schizophrenia drug gains FDA approval.
Price battle over schizophrenia drug.
Schizophrenia: encouraging outlook emerges.
Schizophrenia: promising drug ... and infectious clues.
New schizophrenia therapy shows promise.
Schizophrenia.
When Someone Has Schizophrenia.
Back from the Brink.
A beautiful mind. (Comments).
Schizophrenia syncs fast: disconnected brain may lie at heart of disorder.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters